WOBURN, Mass.--(BUSINESS WIRE)--BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that a Phase 3 pivotal study with OncoVEXGM-CSF for the first line treatment of patients with locally advanced squamous cell carcinoma of the head & neck (SCCHN) has commenced. The study will be conducted across sites in the US and the UK. Further details on this study can be found at www.clinicaltrials.gov.
